A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
By R. Goldberg, D. Sargent, R. Morton, C. Fuchs, R. Ramanathan, S. Williamson, B. Findlay, H. Pitot, S. Alberts. Journal of Clinical Oncology, 2004
2,302 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/37fc316ea871c7761e25f018c54d5d22293d668f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “FOLFOX note 1 [162, 163] + BEV [164] CAPOX + BEV [164, 165] SOX + BEV [157] Fig.”
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial (2017, background): “receiving these agents in any sequence surviving a median 18 to 20 months.(5,6)”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bma”
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. (2008, methodology): “1 FOLFOX also improved response and survival compared with irinotecan plus bolus FU and LV (IFL) in US Intergroup Study N9741.”
- Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. (2005, background): “‘Non-selected’ patients in phase III trials Goldberg [ 60 ] 264 IFL 31 2 1%”
- Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (2007, background): “The team hould include individuals with expertise necessary to (1) ssume overall medical management of the cancer patient, 2) perform vascular catheterization, (3) perform and interret radiologic scans, (4) assume responsibility for the de-”